ATBECHDEDKESFRGBGRITLILUNLSEMCPTIE......FI..........................................................JDIM360 Ver 2.15 (14 Jul 2008) - 2999001/01162272CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120091021W154deBibliographieenBibliographyfrBibliographieEP01113517.5199606262005011020060407enenen50030619950710US2009102120094320011212200150200811052008452008040820091021200943C12N 15/57 20060101AFI20040206BHEP C12N 9/64 20060101ALI20040206BHEP C12N 15/86 20060101ALI20040206BHEP C07K 16/30 20060101ALI20040206BHEP A61K 38/43 20060101ALI20040206BHEP deHerstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (SPA)enGeneration of immune responses to prostate-specific antigen (SPA)frGénération de réponses immunitaires à l'antigène spécifique de la prostate (SPA)EP-A- 0 652 014EP-A- 0 725 139WO-A-95/04548ZA-A- 9 401 645HODGE J W ET AL: "A recombinant vaccinia virus expressing human prostate - specific antigen (PSA): Safety and immunogenicity in a non-human primate." INTERNATIONAL JOURNAL OF CANCER 63 (2). 1995. 231-237. ISSN: 0020-7136, XP000605674CORMAN J M ET AL: "Prostate specific antigenic peptides induce T - cell proliferation in-vitro: A model for the development of prostate specific tumor vaccines." NINETY-FIRST ANNUAL MEETING OF THE AMERICAN UROLOGY ASSOCIATION, ORLANDO, FLORIDA, USA, MAY 4-9, 1996. JOURNAL OF UROLOGY 155 (5 SUPPL.). 1996. 528A. ISSN: 0022-5347, XP000604547CORRELAE P ET AL: "Generation of human T - cell lines specific for prostate specific antigen using an oligo-epitope peptide." 87TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, D.C., USA, APRIL 20-24, 1996. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 37 (0). 1996. 488-489. ISSN: 0197-016X, XP002018984LU, EDWARD W. ET AL: "Factors affecting production of antibodies to prostate antigens by in vitro-primed human splenocytes" HYBRIDOMA (1993), 12(4), 381-9 CODEN: HYBRDY;ISSN: 0272-457X, 1993, XP000605666P. CORREALE ET AL.: "In vitro stimulation of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen." 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, no. 3449, 1 January 1995 (1995-01-01), page 582, XP000607089J. KANTOR ET AL.: "Immunogenicity and safety of a recombinant Vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate." CANCER RESEARCH, vol. 52, 15 December 1992 (1992-12-15), pages 6917-6925, XP000605381ABULAFIA R ET AL: "IN-VITRO PRODUCTION OF T CELLS IMMUNOREACTIVE AGAINST PROSTATE SPECIFIC ANTIGEN A NOVEL APPROACH FOR AN ANTIGEN - SPECIFIC ADOPTIVE IMMUNOTHERAPY PROGRAM FOR PROSTATE CANCER." JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS, LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J 4 (7). 1990. A2021. CODEN: FAJOEC ISSN: 0892-6638, XP002018985ROSS S ET AL: "Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): Results from a pilot study." BIOTECHNOLOGY THERAPEUTICS 4 (3-4). 1993. 197-211. ISSN: 0898-2848, XP000605665E. PAOLETTI ET AL.: "Immunotherapeutic stategies for cancer using poxvirus vectors." ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 690, 1993, pages 292-300, XP000605669J.F. DONOVAN ET AL.: "Immunotherapy of prostate cancer." PROBLEMS IN UROLOGY, vol. 4, no. 3, September 1990 (1990-09), pages 489-505, XP000604543KAUFMAN H.L. ET AL: 'Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group.' JOURNAL OF CLINICAL ONCOLOGY vol. 22, no. 11, 01 June 2004, pages 2122 - 2132KAUFMAN H.L. ET AL: 'Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897' JOURNAL OF CLINICAL ONCOLOGY vol. 23, no. 16S, 01 June 2005, page 4501MARSHALL J.L. ET AL: 'Phase I study in cacner patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.' JOURNAL OF CLINICAL ONCOLOGY vol. 17, no. 1, 1999, pages 332 - 33796923417.8084079119970130Schlom, Jeffrey National Cancer Institute10 Center Drive, Bldg 10, Room 8B09Bethesda, Maryland 20892USPanicali, Dennis, Therion Biologics Corporation76 Rogers StreetCambridge, Massachusetts 02142USTHE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services08203350HL80158/018/DLB6011 Executive Boulevard, Suite 325 Office of Technology TransferRockville, MD 20852USBrown, David Leslieet al00059144Haseltine Lake LLP Redcliff Quay 120 Redcliff StreetBristol BS1 6HUGB01200908051OXFORD BIOMEDICA (UK) LTD. Medawar Centre00154580Robert Robinson Avenue The Oxford Science ParkOxford OX4 4GAGBO'Brien, Simon Warwicket al09292121D Young & Co 120 HolbornGB-London EC1N 2DYGBATBECHDEDKESFIFRGBGRIEITLILUMCNLPTSE20040714200429